Developments in the EU medicines regulatory network

Slides:



Advertisements
Similar presentations
Registration in Europe Current situation and future outlook Thomas K ü rner, M.D. Nippon Boehringer Ingelheim Co., Ltd.
Advertisements

Health and Consumers Health and Consumers Proposal for new EU Animal Health Regulation European Parliament, Intergroup on the welfare & conservation of.
Health & Consumer Protection Directorate General The EU Health Strategy and the new Health and Consumer Protection Programme Bernard Merkel Paula.
The Paediatric Regulation
Health and Consumers Health and Consumers ECPA/ECCA Regulatory conference on March 2014 Developments in the area of pesticide residues – Commission.
Slide 1 November 2008 Name Sarah Morgan © Crown copyright 2005 Pharmacovigilance Working Party - Role and future perspective Sarah Morgan Medicines and.
1 Reform of the EU regulatory framework for electronic communications What it means for Access to Emergency Services Reform of the EU regulatory framework.
1 The European Paediatric Initiative Agnès Saint Raymond, MD Scientific Advice and Orphan Drugs The European Medicines Evaluation Agency.
An agency of the European Union Presented by: David Mackay Head of Unit, Veterinary Medicines & Product Data Management Unit Incident Management Plan Veterinary.
Authorisation of medicinal products: selected challenges Rocío Salvador Roldán Pharmaceuticals Unit/DG SANCO This presentation only reflects the views.
Implementation of EU Electronic Communication Directives.
Review of veterinary medicines legislation in 2010 Mario Nagtzaam Unit F2 „Pharmaceuticals“ Directorate-General Enterprise and Industry European Commission.
Recommendation 2001/331/EC: Review and relation to sectoral inspection requirements Miroslav Angelov European Commission DG Environment, Unit A 1 Enforcement,
EC actions against the rising threats from Antimicrobial Resistance
Invasive Alien Species REFIT Process The perspective from European hunters Meeting of the Directors-general of Hunting and Game management – 1 st of September.
The current legal situation
Istanbul April 2011 Dr Joe Collins MVB PhD CBiol FSB MRCVS CertEP CertVR VMPs: - Availability - MUMS - Cascade.
June 2009 Regulation on pesticide statistics Pierre NADIN ESTAT E1- Farms, agro-environment and rural development
PharmacoVigilance: Development of PhV systems and processes.
Role of VICH and VICH guidelines in the approval process for veterinary medicinal products David Mackay, European Medicines Agency VICH Workshop – Dar.
JMAFF (Chair of Biologicals Quality Monitoring EWG)
Health and Food Safety EU strategy for Pharmaceuticals in the Environment Patrizia Tosetti DG SANTE European Commission China/EU Pharmaceutical Industry.
National workshop Pilot testing of Guidelines for updating of national implementation plans to address the new persistent organic pollutants in Abuja,
1 VICH AND VETERINARY MEDICINES AVAILABILITY VICH5 CONFERENCE, OCTOBER 2015, TOKYO VICH AND VETERINARY MEDICINES AVAILABILITY VICH5 CONFERENCE, OCTOBER.
PharmacoVigilance: Development of PhV systems and processes VICH Workshop, Dar Es Salaam, Tanzania, 24 June 2015.
An agency of the European Union Principles for the assessment and authorisation of antimicrobials in the EU VICH Outreach Forum, October 2015 Presented.
Date Insert on Master Slide Slide 1 Regulatory Framework within which patients can have safe and more convenient access to medicines Royal College of Physicians.
Slide 1 The contribution of a world-class regulatory environment to the future of the industry in Ireland Pat O’Mahony Chief Executive, Irish Medicines.
IADSA Scientific Forum 2009 The scientific substantiation of health claims David P. Richardson Scientific Adviser to UK Council for Responsible Nutrition.
ICORD 2006 Kerstin Westermark Md, PhD, Assoc. prof. COMP Chairperson.
1 1 Topics “out of the scope of VICH” Brigitte Boenisch IFAH-Europe 2 nd VICH Outreach Forum Meeting Washington, 19 th /20 th February 2012 – how and by.
1 The contribution of VICH to the global One Health approach VICH5 CONFERENCE, OCTOBER 2015, TOKYO Jean-Pierre Orand, Anses, France, OIE Collaborating.
1 Package on food improvement agents Food additives Food enzymes Flavourings Common procedure Developments since earlier consultation.
POST APPROVAL CHANGE MANAGEMENT PROTOCOLS IN THE EUROPEAN UNION
Update on EU regulatory developments
INSPIRE and the role of Spatial Data Interest Communities (SDIC)
VICH General Principles and
Periodic Safety Update Reports (PSUR)
Information on Medicinal Products
Speedy Assessment of Vaccines: EMA’s toolbox
REGULATORY PROBLEMS IN CARING OUT PRE- AND POST- AUTHORISATION CLINICAL TRIALS Dr Penka Decheva GCP Inspector, BDA.
Session 2 - Agenda Item 10.2.: EMA
Multinational collaboration in the Authorisation of VMPs: the EU approach VICH Outreach Forum Tokyo, Nov 2017 Noel Joseph European Commission.
TAIEX, Istanbul, April 19th, 2011
Union referral procedures
Vytenis Andriukaitis European Commissioner for Health and Food Safety
EMA Working Groups on Committees' Operational Preparedness
Helen Lee, European Commission
Waiving Target Animal Batch Safety Testing for vaccines
EU Reference Centres for Animal Welfare
Maintaining joint packaging and labelling into the future
CCMI 9 September 2015 Public Hearing: Nanotechnology for a competitive chemical industry Social aspects: education, health and safety.
The 3Rs principles for safety testing of human and veterinary medicines A view on the EU regulatory developments in 3Rs (replacement, reduction, refinement)
Stefan Berggren Marine and Water director, Sweden
The Benefits of VICH to Emerging Countries
Stefan Berggren Marine and Water director, Sweden
ETS WG, 31 January-2 February 2005
The proposed legislation
HPRA preparedness for Brexit
Changing the Reference Member State (RMS)
HPRA delivery on strategic plan
Jane Lenehan, Scientific Animal Protection Manager (acting)
Water Framework Directive 2000/60/EC
Working Group on Rail Transport Statistics
Water scarcity and drought
Pharmacovigilance inspections: what HPRA expects
An introduction to EMA’s support for medicines development
EUnetHTA Assembly May 2018.
Update on EU draft Regulation
European Safety Survey : News on the draft Council and European Parliament Regulation Task Force Victimisation 17 February 2011.
Presentation transcript:

Developments in the EU medicines regulatory network David Murphy Veterinary Information Day 2018 13th June, Hilton Hotel Dublin Airport

Theme 2: Contributing to animal health and human health in relation to veterinary medicines 10/04/2019

CVMP priority areas of activity 2018 ITF, ADVENT (Q+As for stem cells and mAbs), scientific advice MUMS classification/guidelines Supporting product development Field efficacy studies for vaccines VAMF Measures to promote availability of vaccines in emergency situations Availability (vaccines) Continue work on GL on risk assessment of AMs AMEG on antimicrobial categorisation Finalise ‘pilot’ on SPC harmonisation of ‘established’ antimicrobials Antimicrobial resistance 10/04/2019

Other activity (some recently adopted CVMP documents) GL on user safety of topically administered veterinary medicinal products GL on assessing the environmental and human health risks of VMPs in groundwater GL on the chemistry of active substances for VMPs GL on a phased implementation of requirements to control elemental impurities in VMPs Guidance for individual laboratories for transfer of quality control methods validated in collaborative trials with a view to implementing 3Rs Reflection paper on the dissolution specification for generic solid oral immediate release products with systemic action Reflection paper on the chemical structure and properties criteria to be considered for the evaluation of new active substance status of chemical substances in MAAs for VMPs Reflection paper on promotion of pharmacovigilance reporting 10/04/2019

Consumer safety – diethanolamine, MRLs for biologicals Other activity……. Consumer safety – diethanolamine, MRLs for biologicals Environment – PBTs, VMPs in aquaculture, AMR Pharmacovigilance – post-marketing surveillance based on signal detection, develop strategy on safety communication Quality – histamine in gentamicin-containing VMPs for horses Training – reinforce scientific and regulatory capacity 10/04/2019

Challenges for the Network 10/04/2019

Loss of UK contribution to the Network Loss of UK capacity and expertise has the potential to stress the network Responsible for ~20% of CAPs, ~30% MRP/DCP Significant contributor to assessment activity as non-lead MS Significant contributor at all CVMP WPs, CMDv 10/04/2019

10/04/2019

Relocation – impact Not expected to negatively impact on the holding of CVMP meetings or assessment procedures Not expected to negatively impact on the holding of CMDv meetings May impact on physical meetings of CVMP working groups Reduction in secretariat support for WP activities potential to impact on CVMP priority areas of activity

The new veterinary regulation Objectives: increase the availability of veterinary medicinal products; reduce administrative burdens; stimulate competitiveness and innovation; improve the functioning of the internal market; and address the public health risk of antimicrobial resistance (AMR) - Without compromising protection of public and animal health 10/04/2019

Impact on scientific committees of EMA Explicit requirements Provide scientific advice on request to the European Commission as part of consultation in drawing up delegated and implementing acts specified in the regulation Implicit requirements (examples) Endorse new and revised guidance which involve CVMP and its working parties (e.g. Good Pharmacovigilance Practice, list of variations requiring assessment) Provide scientific advice to the EC on other obligations in the new veterinary regulation (e.g. in relation to ERA, withdrawal periods under the cascade) 10/04/2019

Phases of delegated and implementing acts related to the NVR 12 months before date of application Entry into force Date of application It is assumed that the regulation will ‘be applied’ three years later (i.e. become operable) 2018 Aujourd'hui 366 jours 367 jours 366 jours Within 5 years from the date of application It is assumed that the regulation will enter into force (i.e. be adopted by Council and Parliament) by the end of 2018 or first quarter of 2019. Note: Others with no timeline

Examples of likely future activity to support NVR Dossier data requirements Provide advice to the European Commission on request on revision of the technical annexes to the regulation to Reflect the content of the revised regulation e.g. Requirements for biological products Requirements for MUMS and authorisations under exceptional circumstances Reflect scientific progress since last revision Incorporate changes to promote availability 10/04/2019

Examples of likely future activity to support NVR Antimicrobials To define criteria for restricting antimicrobial substances to use in man (i.e. not for use in animals) and to propose lists of antimicrobials not to be used in animals To propose lists of antimicrobials the use of which should be restricted under the prescribing ‘cascade’ (i.e. off label use) To advise on scientific aspects related to collection of data by Member States on use of antimicrobials in different animal species 10/04/2019

Examples of likely future activity to support NVR Pharmacovigilance To provide advice on guidance on Good Pharmacovigilance for VMPs taking into account the changes introduced (e.g. phase out of routine PSURs and move to system based on signal management, new obligations on MAH) ERA Acceptable use of PBT substances as VMPs Advice on feasibility of monograph system for ERA of active substances 10/04/2019

Brexit will challenge the Network Summary Brexit will challenge the Network capacity and expertise relocation HMA and EMA are working to minimise disruption Redistribution of UK product portfolio Capacity building Developing available expertise EMA business continuity plan 10/04/2019

Summary New Veterinary Regulation will introduce substantial changes to the system of authorisation of VMPs For the Network, the anticipated workload is high and the timescale for implementation is ambitious The work programmes of the CVMP and its working parties will be amended to take into account the new tasks arising Given the proposed ‘phased’ application of delegated and implementing actions, there will be a period of change up to and after the date the NVR becomes operable. 10/04/2019

Thank you vetinfo@hpra.ie www.hpra.ie Follow @TheHPRA